Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of S64315 in acute myeloid leukemia or myelodysplastic syndrome
NL-OMON48784Phase 1Withdrawn
- Sponsor
- Servier
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of S64315 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Servier. Planned start Jun 2018; status: withdrawn.
02
Drugs
S64315
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON48784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48784.